Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
Outcomes-based reimbursement agreement are becoming increasingly popular in Europe. They’re complicated, there’s no “one size fits all” and it’s important companies and payers alike know what’s involved, says a forthcoming report.
The Scottish Medicines Consortium has recommended EUSA’s ultra-orphan neuroblastoma treatment Qarziba.
Medicines regulators in Mexico and Argentina have agreed to exchange good manufacturing practices inspection certificates.
Providing access to unlicensed medicines can offer companies big strategic advantages.
Providing access to novel medicines through early access programs or supplying markets where medicines remain unlicensed has key benefits for the innovative drug development industry; revealing market insights and strategic opportunities.
The Pink Sheet looks at the impact Brazil’s divisive new president elect might have on healthcare and the pharmaceutical industry. Top-level reorganization or depleted healthcare budgets?